DR. HÖNLE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.85 EUR | -0.25% |
|
-0.75% | +13.43% |
| Feb. 26 | Dr. Hönle AG Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
| Jan. 25 | Dr. Hönle AG Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 41.35 and 14.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.43% | 129M | C- | ||
| +12.62% | 82.83B | A- | ||
| +17.86% | 69.72B | B | ||
| +20.14% | 37.53B | B- | ||
| +14.52% | 31.66B | A | ||
| +13.02% | 27.96B | B- | ||
| +2.46% | 26.56B | C+ | ||
| +14.45% | 25.65B | B+ | ||
| +2.11% | 25.46B | B+ | ||
| +15.63% | 24.44B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HNL Stock
- Ratings Dr. Hönle AG
